alvac ny eso-1 vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00670748)
Timeline
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, active
Cancer/testis antigen 1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alvac(2)-ny-eso-1 (m)/tricom vaccine
- alvac ny eso-1 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01982487 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01536054 | Phase 1 | Aug 20, 2012 | National Cancer Institute (NCI), Sanofi-Aventis, State University of New York, Buffalo |
| NCT00803569 | Phase 1 | Nov 1, 2008 | Ludwig Institute for Cancer Research, State University of New York, Buffalo |
| NCT00670748 | Phase 2 | Apr 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2008 |
| State University of New York, Buffalo | Academic/Hospital | 3 | 2 | 2 | 2008 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2008 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2008 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1